GlassScriptPhysician profile
John G Dawkins
NPI 1871799213
$2,226.63
in general payments reported to CMS, 2019-2025
26 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $397 · 2021: $501 · 2022: $24.87 · 2023: $321 · 2024: $19.15 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $290.74 | 2021-2023 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $233.80 | 2019-2025 | Gardasil 9, Capvaxive |
| Allergan, INC. | $218.05 | 2019-2020 | |
| Abbvie INC. | $165.11 | 2021 | |
| Alnylam Pharmaceuticals INC. | $146.21 | 2025 | Amvuttra |
| Novo Nordisk INC | $122.38 | 2019-2023 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $114.21 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.30 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $97.48 | 2019 | |
| Pfizer INC. | $95.39 | 2019-2021 | |
| Amgen INC. | $74.04 | 2019-2023 | Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $73.77 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $64.21 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.41 | 2019 | |
| Gilead Sciences, INC. | $59.13 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $56.92 | 2019-2023 | Mounjaro |
| Astellas Pharma US INC | $42.19 | 2019-2024 | Veozah |
| Phadia US INC. | $38.23 | 2021 | |
| Sanofi-Aventis U.S. LLC | $33.67 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $31.21 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $26.83 | 2019 | |
| Antares Pharma, INC. | $18.02 | 2021 | |
| Shire North American Group INC | $16.89 | 2019 | |
| Genentech USA, INC. | $14.58 | 2019 | |
| Avion Pharmaceuticals | $14.47 | 2020 | |
| Therapeuticsmd, INC. | $14.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dawkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.